NL-OMON45448已完成不适用
VLDL1, VLDL2, and LDL apolipoprotein B-100 kinetics in patients with familial hypercholesterolemia of unknown origin (FH4) - APPRECIATIO
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Diagnosis of familial hypercholesterolemia of unknown origin (FH4) based on Dutch Lipid Clinic Network criteria (Nordestgaard et al. 2013) and negative DNA-testing (mutations in LDLR, ApoB, PCSK9).
- •- Untreated LDL-cholesterol levels of > 95th percentile for affected members
- •- 18-65 years of age;Controls:
- •- Unaffected family member with untreated LDL-cholesterol between 20-60th percentile
- •- 18-65 years of age
- •- Persons with mutations in LDLR, APOB, or PCSK9 gene or other genes involved in lipid metabolism.
- •- 18-65 years of age
排除标准
- •· Heavy alcohol use
- •· Dysthyroidism
- •· Pregnancy, breastfeeding
- •· Renal insufficiency (creatinine >150 µmol/L)
- •· Diabetes mellitus
研究者
相似试验
已完成
2 期
A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin ineligible, locally advanced or metastatic urothelial cancer patientsbladder cancerNL-OMON49675PPD6
已完成
3 期
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)1) Unresectable stage IIIB to IVM1c melanoma2) Unremoved melanoma (type of skin cancer)10040900NL-OMON50729Amgen15
已完成
不适用
Whole blood thrombin generation, platelet activation test and platelet-monocyte complex formation to predict hypercoagulability in patients with multiple myelomacancer of plasma cellsPlasma cell myeloma10018865NL-OMON48375Synapse Research Institute42
已完成
2 期
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta ThalassemiaBeta Thalassemiainherited blood disorder10038158NL-OMON54921IMARA, Inc.15
已完成
不适用
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid TumorsCancerNL-OMON48631Merck KGaA7